ZNF22

Across TCGA pan-cancer cohorts, ZNF22 mass-spec protein is linked to patient survival in 3 of 34 cancer types, making it a survival-associated ZNF22 data layer compared with 25 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher ZNF22 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated ZNF22 expression acts as an unfavorable survival marker, although some lineages such as PDAC show a favorable association.

LUAD, PDAC, and HNSC are the cancer types where ZNF22 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	OS	Median	II,III,IV	0.468	0.874	.039	4	view →
PDAC	DFS	Median	IV	0.752	0.250	.024	3	view →
HNSC	OS	Quartile	III,IV	0.811	0.966	.047	1	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

ZNF22–LUAD (OS)

Open the LUAD breakdown →